Engineering of macrophages to produce IFN-γ in response to hypoxia

被引:43
作者
Carta, L
Pastorino, S
Melillo, G
Bosco, MC
Massazza, S
Varesio, L
机构
[1] Ist Giannina Gaslini, Mol Biol Lab, I-16147 Genoa, Italy
[2] NCI, Dev Therapeut Program, Tumor Hypoxia Lab, Sci Applicat Int Corp, Frederick, MD 21702 USA
关键词
D O I
10.4049/jimmunol.166.9.5374
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Activation of murine macrophages (M phi) requires the collaboration of signals derived from the immune system and the environment. In this study, we engineered a murine M phi cell line to become activated in response to an environmental signal, hypoxia, as the sole stimulus. Hypoxia is a condition of low oxygen tension, occurring in several pathological tissues, which acts in synergy with IFN-gamma to induce full M phi activation. We transfected the ANA-1 murine M phi cell line with a construct containing the IFN-gamma gene controlled by a synthetic promoter inducible by hypoxia (HRE3x-Tk), and we characterized the cellular and molecular biology of the engineered M phi under normoxia or hypoxia. Engineered M phi in normoxia expressed basal levels of IFN-gamma mRNA and protein that were strongly augmented by shifting the cells to hypoxia. Furthermore, they responded to the synthesized IFN-gamma with induction of IFN-responsive factor-1 and 2'-5'-oligoadenylate synthase expression. Under normoxic conditions, the engineered M phi had a significant constitutive level of la Ags and Fc receptors. Hypoxia induced further augmentation of Ia and Fe expression. Finally, hypoxia induced inducible NO synthase expression, and subsequent reoxygenation led to the production of NO. In conclusion, the engineered M phi, which produce IFN-gamma in an inducible manner, express new biochemical and functional properties in response to low oxygen environment as the sole stimulus, thereby circumventing the need for costimulation by other immune system-derived signals.
引用
收藏
页码:5374 / 5380
页数:7
相关论文
共 37 条
[1]   Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34+ cells [J].
An, DS ;
Wersto, RP ;
Agricola, BA ;
Metzger, ME ;
Lu, S ;
Amado, RG ;
Chen, ISY ;
Donahue, RE .
JOURNAL OF VIROLOGY, 2000, 74 (03) :1286-1295
[2]   Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives [J].
Andreesen, R ;
Hennemann, B ;
Krause, SW .
JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 64 (04) :419-426
[3]   A MURINE MACROPHAGE CELL-LINE, IMMORTALIZED BY V-RAF AND V-MYC ONCOGENES, EXHIBITS NORMAL MACROPHAGE FUNCTIONS [J].
BLASI, E ;
RADZIOCH, D ;
DURUM, SK ;
VARESIO, L .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1987, 17 (10) :1491-1498
[4]   IL-2 signaling in human monocytes involves the phosphorylation and activation of p59hck [J].
Bosco, MC ;
Curiel, RE ;
Zea, AH ;
Malabarba, MG ;
Ortaldo, JR ;
Espinoza-Delgado, I .
JOURNAL OF IMMUNOLOGY, 2000, 164 (09) :4575-4585
[5]  
COX D, 1992, J PROTOZOOL RES, V2, P149
[6]   INVIVO GENE-TRANSFER WITH RETROVIRAL VECTOR PRODUCER CELLS FOR TREATMENT OF EXPERIMENTAL BRAIN-TUMORS [J].
CULVER, KW ;
RAM, Z ;
WALLBRIDGE, S ;
ISHII, H ;
OLDFIELD, EH ;
BLAESE, RM .
SCIENCE, 1992, 256 (5063) :1550-1552
[7]   Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis [J].
Fathallah-Shaykh, HM ;
Zhao, LJ ;
Kafrouni, AI ;
Smith, GM ;
Forman, J .
JOURNAL OF IMMUNOLOGY, 2000, 164 (01) :217-222
[8]  
FOLKMAN J, 2000, EXS, V79, P1
[9]  
Forni G, 2000, CANCER RES, V60, P2571
[10]  
GENDELMAN HE, 1994, MACROPHAGE, P157